PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25996294-9	2015	We validated RIPK1, RIPK3 and transforming growth factor-beta-activated kinase 1 (TAK1) as novel, direct targets of ponatinib by using competitive binding, cellular thermal shift and recombinant kinase assays.	ponatinib	116-125	receptor interacting serine/threonine kinase 3	Homo sapiens	20-25	
25996294-10	2015	Ponatinib inhibited both RIPK1 and RIPK3, while pazopanib preferentially targeted RIPK1.	ponatinib	0-9	receptor interacting serine/threonine kinase 3	Homo sapiens	35-40	
25801024-2	2015	In the current work, we report that the Bcr-Abl inhibitor and anti-leukemia agent ponatinib is also a first-in-class dual inhibitor of RIPK1 and RIPK3.	ponatinib	82-91	receptor interacting serine/threonine kinase 3	Homo sapiens	145-150